Cephalon moves into biologics with Arana acquisition
This article was originally published in Scrip
Executive Summary
Cephalon has completed its acquisition of all the outstanding ordinary shares of the Australian biotech firm Arana Therapeutics. It acquired a controlling stake in the company in May.